IPP Bureau
Deep Lens and Pacific Cancer Centre collaborate to improve clinical trials
By IPP Bureau - October 11, 2021
VIPER AI solutions support care teams by automating the identification of potentially eligible patients at the time of diagnosis and easily matching them to relevant trials
Astra’s antibody injection trial indicates it can prevent and treat Covid-19
By IPP Bureau - October 11, 2021
AZD7442 reduced risk of developing severe Covid-19 or death in Tackle Phase III outpatient treatment trial
IDFC FIRST Bank & Banyan Academy launch Centre for Trauma Studies & Innovation
By IPP Bureau - October 11, 2021
Through this initiative, the Centre for Trauma will create curriculums and facilitate trauma-related courses for healthcare professionals at both urban and grassroot levels
HealthEdge opens its facility in Pune
By IPP Bureau - October 11, 2021
The Pune centre expands its presence beyond Bangalore and Hyderabad
Kaneka Covid-19 kits detect all four variants simultaneously
By IPP Bureau - October 11, 2021
The test kit uses a reagent developed using Kaneka's molecular testing-related technologies
Merck and Ridgeback seek EUA from U.S. FDA for molnupiravir
By IPP Bureau - October 11, 2021
If authorized, molnupiravir could be the first oral antiviral medicine for the treatment of Covid-19
Sai Life Sciences presents its midterm report
By IPP Bureau - October 11, 2021
The company has enabled a transformation across three core areas with an investment target of US $ 150 million
AstraZeneca India launches solar project to achieve sustainability goals
By IPP Bureau - October 11, 2021
The company will shift 100 percent of its energy use to renewable sources for both power and heat by 2025 in order to achieve carbon neutrality
Gland Pharma receives tentative nod for Sugammadex injection
By IPP Bureau - October 09, 2021
The injection is used to reverse the effects of the muscle relaxants given to patients during surgery
Cyprium Therapeutics and Sentynl, a Zydus subsidiary announce positive data for CUTX-101, CuHis
By IPP Bureau - October 09, 2021
The rolling submission to the U.S. FDA will begin in the fourth quarter of this year
Roche’s Alzheimer antibody granted U.S. FDA Breakthrough Therapy Designation
By IPP Bureau - October 09, 2021
Gantenerumab is an investigational antibody in Phase III development for early Alzheimer's disease (AD) and a comprehensive data set with an expected readout in mid-2022
Tezepelumab granted Orphan Drug Designation in the US
By IPP Bureau - October 09, 2021
Tezepelumab has been granted Orphan Drug Designation (ODD) in the US by the U.S. Food and Drug Administration (FDA) for the treatment of eosinophilic esophagitis (EoE)
Govt clarifies on export ban of syringes
By IPP Bureau - October 09, 2021
Quantitative restrictions in place to meet domestic needs to cater to the vaccination programme
Alnylam partners with the Medicines Manufacturing Innovation Centre
By IPP Bureau - October 09, 2021
Alnylam is the latest partner in the Medicines Manufacturing Innovation Centre’s third Grand Challenge project, which aims to revolutionise the manufacturing process for oligonucleotide therapies
ASU drug manufacturing licence goes online
By IPP Bureau - October 09, 2021
The applicants will only have to get their Good Manufacturing Practices certification validated every five years to retain their licence
